← Leaderboards
Peter Vanderslice
7 Hills Pharma, Llc
$1,627,443
Attributed
$3,254,885
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $936K · FY2016–23$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,254,885 · 3
By mechanism
R42$1,864,898 · 1
R33$1,094,056 · 1
R41$295,931 · 1
Top collaborators
- Upendra Marathi3 shared
- Ronald J Biediger2 shared
Others in their field
Top investigators on “Hematologic Neoplasms”
- Ronald T Mitsuyasu · University Of California Los Angeles$101,827,988
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Suzanne George · Brigham And Women'S Hospital$34,879,352
- Paul M. Ridker · Brigham And Women'S Hospital$34,275,148
- Norman Wolmark · Nsabp Foundation, Inc.$33,598,810
- Robert S Mannel · University Of Oklahoma Hlth Sciences Ctr$33,598,810
Research focus
Hematologic NeoplasmsHuman Cord Blood Cd34+ CellEngraftmentGraft FailureHematopoietic Stem CellsHomingDoseCell Adhesion MoleculesExtravasationFutureClinical TrialsDrug KineticsChemokineHematopoietic Stem Cell TransplantationAdhesionsCellsBlood CellsCell AdhesionDisadvantagedBone MarrowApplications GrantsFamilyAdultImproved Outcome
Grant awards (5)
Optimization of small molecule integrin activators to enhance cord blood transplant$547,028
R33 · FY2023 · HL · contact PI
Optimization of small molecule integrin activators to enhance cord blood transplant$547,028
R33 · FY2022 · HL · contact PI
A small molecule integrin activator to enhance cord blood transplant$928,941
R42 · FY2021 · HL · contact PI
A small molecule integrin activator to enhance cord blood transplant$935,957
R42 · FY2020 · HL · contact PI
A small molecule integrin activator to enhance cord blood transplant$295,931
R41 · FY2016 · HL · contact PI